Search This Blog

Friday, July 2, 2021

Lottery-based incentives do not increase COVID-19 vaccination rates: study

 Would you be more willing to get vaccinated against the COVID-19 virus if you could participate in a lottery for cash and prizes? The answer was surprisingly no, according to Boston University School of Medicine (BUSM) researchers who found that Ohio's "Vax-a-Million" lottery-based incentive system, intended to increase COVID-19 vaccination rates, was not associated with an increase in COVD-19 vaccinations.

Prior reports in the media had suggested that the Ohio lottery increased COVID-19 vaccinations, leading other states to use COVID-19 vaccine incentive lotteries in an attempt to increase slowing . "However, prior evaluations of the Ohio vaccine incentive lottery did not account for other changes in COVID-19 vaccination rates in the United States, such as those that may have been due to expansion of vaccination to ages 12-15," explained corresponding author Allan J. Walkey, MD, MSc, professor of medicine at BUSM.

Using data from the U.S. Centers of Disease Control to evaluate trends in vaccination rates among adults 18 and older, the researchers compared vaccination rates before and after the Ohio lottery versus other states in the U.S. that did not yet have vaccine incentive lottery programs. Vaccination rates in other states served as a "control" for vaccination trends measured in Ohio, allowing the researchers to account for factors besides the Ohio lottery (such expanding vaccine eligibility to adolescents) throughout the country.

"Our results suggest that state-based lotteries are of limited value in increasing vaccine uptake. Therefore, the resources devoted to vaccine lotteries may be more successfully invested in programs that target underlying reasons for vaccine hesitancy and low vaccine uptake," said Walkey, a physician at Boston Medical Center.

The researchers believe identifying interventions that can successfully increase COVID-19 vaccination rates is a critical public health issue necessary to curb the pandemic. "It is important to rigorously evaluate strategies designed to increase vaccine uptake, rapidly deploy successful strategies, and phase out those that do not work," Walkey said.

Although Walkey and his colleagues were sorry to see that state  incentives were not associated with an increase COVID-19 vaccinations, they hope their findings will lead to a shift in focus away from ineffective and expensive lotteries, and on to further study of other programs that may more successfully increase  uptake.


Explore further

Almost all U.S. physicians have gotten a COVID vaccine

More information: Allan J. Walkey et al, Lottery-Based Incentive in Ohio and COVID-19 Vaccination Rates, JAMA (2021). DOI: 10.1001/jama.2021.11048
https://medicalxpress.com/news/2021-07-lottery-based-incentives-covid-vaccination.html

Stress can turn hair gray -- and it's reversible

 Legend has it that Marie Antoinette's hair turned gray overnight just before her beheading in 1791.

Though the legend is inaccurate -- hair that has already grown out of the follicle does not change color -- a new study from researchers at Columbia University Vagelos College of Physicians and Surgeons is the first to offer quantitative evidence linking psychological stress to graying hair in people.

And while it may seem intuitive that stress can accelerate graying, the researchers were surprised to discover that hair color can be restored when stress is eliminated, a finding that contrasts with a recent study in mice that suggested that stressed-induced gray hairs are permanent.

The study, published June 22 in eLife, has broader significance than confirming age-old speculation about the effects of stress on hair color, says the study's senior author Martin Picard, PhD(link is external and opens in a new window), associate professor of behavioral medicine (in psychiatry and neurology) at Columbia University Vagelos College of Physicians and Surgeons.

"Understanding the mechanisms that allow 'old' gray hairs to return to their 'young' pigmented states could yield new clues about the malleability of human aging in general and how it is influenced by stress," Picard says.

"Our data add to a growing body of evidence demonstrating that human aging is not a linear, fixed biological process but may, at least in part, be halted or even temporarily reversed."

Studying hair as an avenue to investigate aging

"Just as the rings in a tree trunk hold information about past decades in the life of a tree, our hair contains information about our biological history," Picard says. "When hairs are still under the skin as follicles, they are subject to the influence of stress hormones and other things happening in our mind and body. Once hairs grow out of the scalp, they harden and permanently crystallize these exposures into a stable form."

Though people have long believed that psychological stress can accelerate gray hair, scientists have debated the connection due to the lack of sensitive methods that can precisely correlate times of stress with hair pigmentation at a single-follicle level.

Splitting hairs to document hair pigmentation Ayelet Rosenberg, first author on the study and a student in Picard's laboratory, developed a new method for capturing highly detailed images of tiny slices of human hairs to quantify the extent of pigment loss (graying) in each of those slices. Each slice, about 1/20th of a millimeter wide, represents about an hour of hair growth.

"If you use your eyes to look at a hair, it will seem like it's the same color throughout unless there is a major transition," Picard says. "Under a high-resolution scanner, you see small, subtle variations in color, and that's what we're measuring."

The researchers analyzed individual hairs from 14 volunteers. The results were compared with each volunteer's stress diary, in which individuals were asked to review their calendars and rate each week's level of stress.

The investigators immediately noticed that some gray hairs naturally regain their original color, which had never been quantitatively documented, Picard says.

When hairs were aligned with stress diaries by Shannon Rausser, second author on the paper and a student in Picard's laboratory, striking associations between stress and hair graying were revealed and, in some cases, a reversal of graying with the lifting of stress.

"There was one individual who went on vacation, and five hairs on that person's head reverted back to dark during the vacation, synchronized in time," Picard says.

Blame the mind-mitochondria connection

To better understand how stress causes gray hair, the researchers also measured levels of thousands of proteins in the hairs and how protein levels changed over the length of each hair.

Changes in 300 proteins occurred when hair color changed, and the researchers developed a mathematical model that suggests stress-induced changes in mitochondria may explain how stress turns hair gray.

"We often hear that the mitochondria are the powerhouses of the cell, but that's not the only role they play," Picard says. "Mitochondria are actually like little antennas inside the cell that respond to a number of different signals, including psychological stress."

The mitochondria connection between stress and hair color differs from that discovered in a recent study of mice, which found that stress-induced graying was caused by an irreversible loss of stem cells in the hair follicle.

"Our data show that graying is reversible in people, which implicates a different mechanism," says co-author Ralf Paus, PhD, professor of dermatology at the University of Miami Miller School of Medicine. "Mice have very different hair follicle biology, and this may be an instance where findings in mice don't translate well to people."

Hair re-pigmentation only possible for some

Reducing stress in your life is a good goal, but it won't necessarily turn your hair to a normal color.

"Based on our mathematical modeling, we think hair needs to reach a threshold before it turns gray," Picard says. "In middle age, when the hair is near that threshold because of biological age and other factors, stress will push it over the threshold and it transitions to gray.

"But we don't think that reducing stress in a 70-year-old who's been gray for years will darken their hair or increasing stress in a 10-year-old will be enough to tip their hair over the gray threshold."

More information

The study is titled "Quantitative Mapping of Human Hair Greying and Reversal in Relation to Life Stress."

All contributors (all from Columbia unless noted): Ayelet Rosenberg, Shannon Rausser, Junting Ren, Eugene V. Mosharov, Gabriel Sturm, R. Todd Ogden, Purvi Patel, Rajesh Kumar Soni, Clay Lacefield (New York State Psychiatric Institute), Desmond J. Tobin (University College Dublin), Ralf Paus (University of Miami, University of Manchester, UK, and Monasterium Laboratory, Münster, Germany), and Martin Picard.

The research was funded by grants from the Wharton Fund and the National Institutes of Health (grants GM119793, MH119336, and AG066828).


Story Source:

Materials provided by Columbia University Irving Medical CenterNote: Content may be edited for style and length.


Journal Reference:

  1. Ayelet M Rosenberg, Shannon Rausser, Junting Ren, Eugene V Mosharov, Gabriel Sturm, R Todd Ogden, Purvi Patel, Rajesh Kumar Soni, Clay Lacefield, Desmond J Tobin, Ralf Paus, Martin Picard. Quantitative mapping of human hair greying and reversal in relation to life stresseLife, 2021; 10 DOI: 10.7554/eLife.67437

Apple lists its products that may 'interfere' with cardiac devices

 Apple has released a long list of products it says should be kept away from implanted pacemakers and defibrillators because it may "interfere" with the medical devices. 

"Many consumer-electronic devices contain magnets or components and radios that emit electromagnetic fields," Apple said, adding that "to avoid any potential interactions with these types of medical devices, keep your Apple product a safe distance away from your medical device (more than 6 inches / 15 cm apart or more than 12 inches / 30 cm apart if wirelessly charging)."

Apple doesn't explain what could happen when its products come in close contact with pacemakers and defibrillators. Still, one could assume the worst circumstance could be the deactivation of a medical device and may result in death. 

"If you suspect that your Apple product is interfering with your medical device, stop using your Apple product and consult your physician and your medical-device manufacturer," the company warned. 

Here are the products Apple wants to keep away from your medical devices: 

AirPods and charging cases

  • AirPods and Charging Case
  • AirPods and Wireless Charging Case 
  • AirPods Pro and Wireless Charging Case
  • AirPods Max and Smart Case

Apple Watch and accessories

  • Apple Watch
  • Apple Watch bands with magnets
  • Apple Watch magnetic charging accessories

HomePod

  • HomePod 
  • HomePod mini

iPad and accessories

  • iPad
  • iPad mini
  • iPad Air
  • iPad Pro
  • iPad Smart Covers and Smart Folios
  • iPad Smart Keyboard and Smart Keyboard Folio
  • Magic Keyboard for iPad

iPhone and MagSafe accessories

  • iPhone 12 models
  • MagSafe accessories

Mac and accessories

  • Mac mini
  • Mac Pro
  • MacBook Air
  • MacBook Pro
  • iMac
  • Apple Pro Display XDR

Beats

  • Beats Flex
  • Beats X
  • PowerBeats Pro
  • UrBeats3

Perhaps Apple's warning comes as a new analysis in the American Heart Association Journal warns that certain Apple iPhones can cause significant issues with cardiac implantable electronic devices. 

https://www.zerohedge.com/medical/apple-warns-iphone-can-interfere-cardiac-devices

Prostate cancer drugs hold potential for treating COVID-19

 Drugs typically used to treat prostate cancer could be explored for treating patients with COVID-19, following encouraging new findings.

Researchers found that the treatment, a type of testosterone-blocker, also reduced the ability of the SARS-CoV-2 coronavirus to infect  cells in the lab.

The work, carried out by cancer researchers at Imperial College London and the University of Essex, is part of larger efforts to find existing drugs which can block COVID-19 by reducing the ability of the virus to enter cells.

The team says the study adds to a growing body of evidence from groups around the world, supporting further  to assess the efficacy of the drugs, called anti-androgens, in the treatment of patients with COVID-19.

Their findings are published in the journal Nature Communications.

Blocking infection

SARS-CoV-2, the virus which causes COVID-19, has been shown to attack multiple organs in the body, but is most destructive to the lungs. In the latest study, researchers focused on one of the proteins used by the virus to enter lung cells, called TMPRSS2, to see if reducing levels could block infection.

Male sex hormones, or androgens, are known to increase levels of TMPRSS2 in several tissues, most notably in the prostate. But drugs used to manage prostate cancer can block androgens, so countering the increase in TMPRSS2 and potentially offering a new treatment option to explore for COVID-19.

The team, co-led by Imperial's Professor Charlotte Bevan and Dr. Greg Brooke from Essex, found that the androgen-blocking  enzalutamide—a well-tolerated drug widely used in —reduced TMPRSS2 levels in lab cultures of human lung cells.

Importantly, they found that the treatment significantly reduced SARS-CoV-2 entry and infection in lung cells. The researchers say their study adds to a growing body of evidence from groups around the world, supporting further clinical trials to assess the efficacy of anti-androgens as a potential treatment for COVID-19.

Potential treatment

Professor Charlotte Bevan, from the Department of Surgery & Cancer, said: "This study not only supports further clinical investigation of these prostate cancer drugs but suggests other drugs we can test that could be useful in the COVID-19 effort. As we have learnt from cancer, it is important to have a range of drugs available in the armory. And drugs that are tried-and-tested and approved in other diseases have the advantage that they can be re-purposed in this way relatively quickly."

Dr. Greg Brooke, from the School for Life Sciences at the University of Essex, explained: "Men are more likely to become seriously unwell and die from COVID-19 compared to women. This suggests the male sex hormone androgen may play a role in SARS-CoV-2 severity.

"For many years I have been working on the role of androgens in  so was able to use this knowledge to investigate if antiandrogens, drugs used for the treatment of , reduce SARS-CoV-2 infection.

"We demonstrated that these drugs reduce the ability of the virus to enter the lungs and, therefore, our data supports clinical trials to investigate if antiandrogens can reduce COVID-19 severity in people infected with the virus."

Two clinical trials assessing anti-androgens in the treatment of COVID-19 are already underway in the United States as well as Sweden, with early findings expected later this year.

"The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells," by et al is published in Nature Communications.


Explore further

Prostate cancer regulator plays role in COVID-19, providing a promising treatment lead

More information: D. A. Leach et al, The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells, Nature Communications (2021). DOI: 10.1038/s41467-021-24342-y
https://medicalxpress.com/news/2021-07-prostate-cancer-drugs-potential-covid-.html

Only 20 states used health equity committees in COVID-19 vaccine distribution planning

 During the large second wave of the COVID-19 pandemic in fall 2020, pulmonologist and critical care provider Juan C. Rojas, MD, reflected on how disproportionately members of minority populations were being affected by the disease. After hearing similar thoughts from colleagues in New Orleans and New York City, Rojas began to wonder how, if at all, state governments planned to ensure these disparities would be addressed when COVID-19 vaccines were rolled out to the public.

In a new study published July 2 in JAMA Network Open, Rojas and his team were surprised to find that while 43 states (out of 51, including all 50 states and Washington, D.C.) created a committee to develop a  distribution plan, only 20 plans mentioned using a health equity committee to assist with plan development. Of those 20 health equity committees, only 8 actually included minority group representatives, with remaining members including physicians, government officials, ethicists and clergy.

"It wasn't surprising to find that there was variability across states, but it was surprising to find that most states didn't have a committee of diverse stakeholders to help address this equity problem," said Rojas, who was senior author on the study. "There weren't many places where patient advocates were included on the committee to add a voice about the additional challenges that might exist for these vulnerable patients."

Additionally, the team found that states used different high-risk criteria and  to determine which group would get priority vaccine access.

"Some states prioritized people over 65, while others prioritize people over 75," said Rojas. "Diabetes and obesity were the most common high-risk conditions listed in the plans we looked at. But then, , which is much more common in African-Americans than in other ethnicities, was only listed as a high-risk condition in 72% of plans. But a high-risk condition is high-risk, no matter what state you live in. This shows that we could do better as a country to develop consistent parameters for these kinds of situations."

The researchers analyzed early versions of these plans, and acknowledge that most remained in "draft" status throughout their analysis since each state's task force continued to adjust and update vaccine rollout efforts. In future studies, the team hopes to investigate how those plans translated to outcomes in vaccine distribution.

"Now that we have more vaccine available, how have these states performed?" said Rojas. "We're looking county by county, and state by state, to see if the equity planning done by individual states actually bore out in better vaccination rates for those high-risk patient populations."

Rojas hopes that this work can be used to help inform ongoing COVID-19 vaccination efforts, but more importantly, that it can help guide policies for potential future healthcare crises.

"The important takeaway here is that having a standardized process in which states and the country can use to roll out something as valuable and complicated as a vaccine to our citizens, with an acknowledgement of existing healthcare disparities," he said. "There need to be conversations about equitable distribution, first by acknowledging that these disparities exist, and then by thinking about how we can create policies that will ensure adequate and equitable access to these vaccines."


Explore further

Data points to Covid vaccine shortfall for Black Americans

More information: Amber Hardeman et al, Evaluation of Health Equity in COVID-19 Vaccine Distribution Plans in the United States JAMA Network Open (2021) DOI: 10.1001/jamanetworkopen.2021.15653
https://medicalxpress.com/news/2021-07-states-health-equity-committees-covid-.html

Assessing impact of short-term musical training on implicit emotion regulation

 Emotion regulation is an essential aspect of mental health and wellbeing. In fact, past studies have found associations between poor emotion regulation and several psychiatric disorders, including bipolar disorder, borderline personality disorder and complex post-traumatic stress disorder (PTSD).

During their everyday life, humans can regulate their negative emotions in different ways, most of which do not require any conscious cognitive engagement. For instance, they might take a bath, step outside for fresh air or listen to .

Researchers at Radboud University Nijmegen in The Netherlands, the Norwegian University of Science and Technology (NTNU), and University Hospital Aachen, Germany have recently carried out a study aimed at investigating the effects of a short-term  on implicit emotion regulation. Their paper, published in BMC Neuroscience, specifically examined whether musical training helped people to reduce the negative emotions elicited by unpleasant or disgusting odors.

"At the time of conception, my colleagues and I worked in the same department in Aachen," Nils Kohn, one of the researchers who carried out the study, told MedicalXpress. "The project was born out of our curiosity for emotions and the power of mood induction that is harbored by music. Mark Berthold-Losleben, being more of a trained musician than myself, was the perfect person to discuss this with."

Kohn, Berthold-Losleben and their colleagues decided to investigate whether, in a controlled environment, music could change people's  responses to unpleasant smells. They focused on olfaction because previous studies found that odors can consistently lead to emotional responses.

Their paper draws on previous knowledge about the stability of olfaction and its neuroanatomical connections, which was gathered by their research group in the past. In addition, it builds on Kohn's theoretical interpretation of how implicit emotion regulation works.

"In the first draft of our paper, we also wanted to explore implicit emotion regulation among professional musicians and/or composers," Berthold-Losleben said. "Therefore, we initiated a cooperation with the school for music and dance in Cologne to recruit participants. Unfortunately, most musicians didn't meet our schedule or the study's inclusion criteria. Another problem was that , or at least those we tried to recruit, did not like the positive auditory stimuli as much as non-professionals did. We assumed that this was because of their professional and therefore more complex approach to music. Maybe our stimuli were too well-known and boring to them."

To investigate the effects of musical training on implicit emotion regulation, Kohn, Berthold-Losleben and their colleagues designed a simple experiment in which they paired negative olfaction (eliciting a negative emotion) with positive music to create four different combinations of stimuli. They then recruited 31 healthy participants to take part in their experiment.

Essentially, participants were either exposed to an odor similar to rotten eggs or to no odors at all. Simultaneously, they either listened to an excerpt of classical music or to a neutral range of tones.

"We then added three weeks of passive listening to classical music as our musical intervention for participants and re-did the test," Kohn explained. "In the task, subjects had to always rate how disgusting the smell was, how they liked the music and how they felt in general. This was done while the subjects lay in the fMRI scanner."

Overall, the findings gathered by the researchers suggest that listening to music two times per day for three weeks can reduce negative emotions elicited by a bad odor, particularly if one hears music again. In other words, music could improve wellbeing and help people to regulate negative emotions elicited by an external stimulus.

If they were also applicable to individuals with , the findings gathered by this team of researchers could have important implications. For instance, they could highlight the value of musical interventions for increasing stress resilience and helping people with affective  to better regulate their emotions.

"Patients suffering from affective disorders like depression often find themselves in an endless circle of sameness," Berthold-Losleben said. "Once confronted with triggers that lead to negative affect, they react with negative emotions/feelings, negative body experiences and negative thinking. All of that itself can trigger a new negative affect. These patients tend to end up in a negative circle or spiral which it is difficult or impossible to get out of."

The overreaching goal of the work by Kohn, Berthold-Losleben and their colleagues is to devise simple musical interventions for people with depression or other affective disorders, which are easy to implement and could improve their ability to regulate negative emotions. Firstly, however, they had to gain a better understanding of emotion  and of the stimuli that can elicit or reduce .

"We are now trying to initiate a collaboration between Radboud University Nijmegen and the Norwegian University of Science and Technology in Trondheim to continue this line of research, as I'm still very interested in what challenges our abilities to regulate ourselves in our daily life and what can support us," Kohn said. "Music would truly be such an easy, powerful and supportive tool for ."


Explore further

Aggressive music related to anxiety in men

More information: Short-term musical training affects implicit emotion regulation only in behavior but not in brain activity. BMC Neuroscience(2021). DOI: 10.1186/s12868-021-00636-1.
https://medicalxpress.com/news/2021-06-neuroscientists-impact-short-term-musical-implicit.html

Potential path to a broadly protective COVID-19 vaccine using T cells

 Gaurav Gaiha, MD, DPhil, a member of the Ragon Institute of MGH, MIT and Harvard, studies HIV, one of the fastest-mutating viruses known to humankind. But HIV's ability to mutate isn't unique among RNA viruses—most viruses develop mutations, or changes in their genetic code, over time. If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes.

To combat HIV's high rate of mutation, Gaiha and Elizabeth Rossin, MD, Ph.D., a Retina Fellow at Massachusetts Eye and Ear, a member of Mass General Brigham, developed an approach known as structure-based . With this, they can identify viral pieces that are constrained, or restricted, from mutation. Changes in mutationally constrained epitopes are rare, as they can cause the virus to lose its ability to infect and replicate, essentially rendering it unable to propagate itself.

When the pandemic began, Gaiha immediately recognized an opportunity to apply the principles of HIV structure-based network analysis to SARS-CoV-2, the virus that causes COVID-19. He and his team reasoned that the virus would likely mutate, potentially in ways that would allow it to escape both natural and vaccine-induced immunity. Using this approach, the team identified mutationally constrained SARS-CoV-2 epitopes that can be recognized by  known as T cells. These epitopes could then be used in a vaccine to train T cells, providing protective immunity. Recently published in Cell, this work highlights the possibility of a T cell vaccine which could offer broad protection against new and emerging variants of SARS-CoV-2 and other SARS-like coronaviruses.

From the earliest stages of the COVID-19 pandemic, the team knew it was imperative to prepare against potential future mutations. Other labs already had published the protein structures (blueprints) of roughly 40% of the SARS-CoV-2 virus, and studies indicated that patients with a robust T cell response, specifically a CD8+ T cell response, were more likely to survive COVID-19 infection.

Gaiha's team knew these insights could be combined with their unique approach: the network analysis platform to identify mutationally constrained epitopes and an assay they had just developed, a report on which is currently in press at Cell Reports, to identify epitopes that were successfully targeted by CD8+ T cells in HIV-infected individuals. Applying these advances to the SARS-CoV-2 virus, they identified 311 highly networked epitopes in SARS-CoV-2 likely to be both mutationally constrained and recognized by CD8+ T .

"These highly networked viral epitopes are connected to many other viral parts, which likely provides a form of stability to the virus," says Anusha Nathan, a medical student in the Harvard-MIT Health Sciences and Technology program and co-first author of the study. "Therefore, the virus is unlikely to tolerate any structural changes in these highly networked areas, making them resistant to mutations."

You can think of a virus's structure like the design of a house, explains Nathan. The stability of a house depends on a few vital elements, like support beams and a foundation, which connect to and support the rest of the house's structure. It is therefore possible to change the shape or size of features like doors and windows without endangering the house itself. Changes to structural elements, like support beams, however, are far riskier. In biological terms, these support beams would be mutationally constrained—any significant changes to size or shape would risk the structural integrity of the house and could easily lead to its collapse.

Highly networked epitopes in a virus function as support beams, connecting to many other parts of the virus. Mutations in such epitopes can risk the 's ability to infect, replicate, and ultimately survive. These highly networked epitopes, therefore, are often identical, or nearly identical, across different viral variants and even across closely related  in the same family, making them an ideal vaccine target.

The team studied the identified 311 epitopes to find which were both present in large amounts and likely to be recognized by the vast majority of human immune systems. They ended up with 53 epitopes, each of which represents a potential target for a broadly protective T cell vaccine. Since patients who have recovered from COVID-19 infection have a T cell response, the team was able to verify their work by seeing if their epitopes were the same as ones that had provoked a T cell response in patients who had recovered from COVID-19. Half of the recovered COVID-19 patients studied had T cell responses to highly networked epitopes identified by the research team. This confirmed that the epitopes identified were capable of inducing an immune reaction, making them promising candidates for use in vaccines.

"A T cell vaccine that effectively targets these highly networked epitopes," says Rossin, who is also a co-first author of the study, "would potentially be able to provide long-lasting protection against multiple variants of SARS-CoV-2, including future variants."

By this time, it was February 2021, more than a year into the pandemic, and new variants of concern were showing up across the globe. If the team's predictions about SARS-CoV-2 were correct, these variants of concerns should have had little to no mutations in the highly networked epitopes they had identified.

The team obtained sequences from the newly circulating B.1.1.7 Alpha, B.1.351 Beta, P1 Gamma, and B.1.617.2 Delta SARS-CoV-2 variants of concern. They compared these sequences with the original SARS-CoV-2 genome, cross-checking the genetic changes against their highly networked epitopes. Remarkably, of all the mutations they identified, only three mutations were found to affect highly networked epitopes sequences, and none of the changes affected the ability of these epitopes to interact with the immune system.

"Initially, it was all prediction," says Gaiha, an investigator in the MGH Division of Gastroenterology and senior author of the study. "But when we compared our network scores with sequences from the variants of concern and the composite of circulating variants, it was like nature was confirming our predictions."

In the same time period, mRNA vaccines were being deployed and immune responses to those vaccines were being studied. While the vaccines induce a strong and effective antibody response, Gaiha's group determined they had a much smaller T cell response against highly networked epitopes compared to patients who had recovered from COVID-19 infections.

While the current vaccines provide strong protection against COVID-19, Gaiha explains, it's unclear if they will continue to provide equally strong protection as more and more variants of concern begin to circulate. This study, however, shows that it may be possible to develop a broadly protective T cell vaccine that can protect against the variants of concern, such as the Delta variant, and potentially even extend protection to future SARS-CoV-2 variants and similar coronaviruses that may emerge.


Explore further

SARS-CoV-2 infections may trigger antibody responses against multiple virus proteins

More information: Anusha Nathan et al, Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses, Cell (2021). DOI: 10.1016/j.cell.2021.06.029
https://medicalxpress.com/news/2021-07-potential-path-broadly-covid-vaccine.html